ライフサイエンスコーパス: TIPS

1 TIPS creation was primarily performed for ascites (159 o

2 TIPS succeeds in lowering the hepatic sinusoidal pressur

3 TIPS volume of </= 20 TIPS/year, variceal bleeding, and

4 TIPS was associated with higher rates of early hepatic e

5 TIPS was technically successful in all 91 patients (12 i

6 TIPS was used more frequently in the tamponade group (4

7 TIPS were placed in all 5529 patients (mean age, 57 year

8 TIPS-acetylene-substituted benzene-1,2-diol and naphthal

9 TIPS-ethynyl groups are not bulky enough to allow stabil

10 ality is lower in hospitals performing >/=20 TIPS per year.

11 TIPS volume of </= 20 TIPS/year, variceal bleeding, and nosocomial infections

12 unique signature of a hidden interface in a TIPS-pentacene thin film, exposing its exciton dynamics

13 onitrile (0-10 degrees C), without affecting TIPS protection of the phenolic hydroxyl in beta-tyrosin

14 nd PV (0.88 L/min; 95% CI: 0.06, 1.70) after TIPS placement (all P < .05), with no significant differ

15 were performed 1 to 7 days before and after TIPS at months 1, 3, 6, 9, and 12 or until liver transpl

16 t to PV flow, were compared before and after TIPS placement by using analysis of variance.

17 oring of hepatic blood flow before and after TIPS placement.

18 of the onset of cardiac decompensation after TIPS and identify the predictive factors.

19 t the concept that PPG value <12 mm Hg after TIPS placement is associated with reduced risk of bleedi

20 ally stable patients at least 24 hours after TIPS to be the best maintained values.

21 V and incomplete patent PV immediately after TIPS was 57.05 +/- 0.75 vs. 39.12 +/- 2.64 months, respe

22 vival and vascular patency immediately after TIPS.

23 sess the epidemiologic findings of LEE after TIPS creation and their association with patient surviva

24 edation (early PPG); and again 1 month after TIPS placement (late PPG).

25 term (>3 months) need for paracentesis after TIPS placement were evaluated and calculated by using th

26 lues measured at different time points after TIPS placement, we found measurements of PPG in awake, h

27 nts collected at different time points after TIPS, aiming to identify a time point after which PPG va

28 y decompensation during the first week after TIPS was observed in only two patients, two and seven 7

29 tory ascites before and 2 and 12 weeks after TIPS placement by using a time-resolved three-dimensiona

30 w-onset or worsened edema up to 1 year after TIPS creation.

31 Patients were followed for 1 year after TIPS insertion.

32 bserved in 20% of patients in the year after TIPS insertion.

33 ollowing EPCS compared with 1.99 years after TIPS.

34 entafluorophenyl 4-maleimidobenzoate (1) and TIPS-protected N-propargyl maleimide (2).

35 to 7 times greater in the EEST ($168100) and TIPS ($264800) groups than in the EPCS ($39000) group (P

36 y greater following EPCS than after EEST and TIPS (P<.001).

37 10-diphenylanthracene, perylene, rubrene and TIPS-pentacene, are reported.

38 more common in hospitals with higher annual TIPS volume (20.3% for very low to 30.8% for very high;

39 s categorized into quintiles based on annual TIPS volume (very low, 1-4/year; low, 5-9/year; medium,

40 Mortality decreased with rising annual TIPS volume (13% for very low to 6% for very high volume

41 Appropriate TIPS procedures were performed based on our more specifi

42 We conclude that appropriate TIPS procedures and lower grade of PVT are essential for

43 ile the use of bulkier silyl groups, such as TIPS, resulted unproductive.

44 cting intervention-free survival and the BCS-TIPS PI score for predicting survival.

45 Before TIPS, MHE was detected by PHES and CFF in 33% and 39% of

46 (triisopropylsilyl)ethynylmagnesium bromide (TIPS-CC-MgBr) leads to a distribution of mono-, bis-, an

47 ere extensively controlled by a remote bulky TIPS group.

48 d by EEST in only 20% of the patients and by TIPS in only 22%.

49 undred seventy-four patients were treated by TIPS during the period.

50 e use of bare stents and most patients chose TIPS 2-3 years after traditional treatment, thus making

51 Collectively, TIPS is an effective and safe approach in treating BCS w

52 Collectively, TIPS is safe and effective in treating liver cirrhosis-r

53 Conclusion TIPS placement in patients with chronic primary BCS was

54 do not have severe extrahepatic conditions, TIPS is an excellent option to treat severe complication

55 Although the corresponding TIPS procedures have already performed on the patients t

56 ic hemostasis for variceal bleeding, covered TIPS was superior to EVL + beta-blocker for reduction of

57 Placement of a small-diameter, covered TIPS was straightforward and prevented variceal rebleedi

58 mly assigned to groups that received covered TIPS (n = 29) or large-volume paracenteses and albumin a

59 ly strained, aligned, and single-crystalline TIPS-pentacene regions with mobility as high as 2.7 cm(2

60 Structurally well-defined TIPS-acetylene substituted tetracene (TIPS-BT1') and pen

61 termolecular interactions led to distinctive TIPS pentacene film morphologies, including randomly-ori

62 Viatorrs were accidentally dislodged during TIPS procedure.

63 ks up when the two triplets separate to each TIPS-pentacene molecule.

64 In E. indica, the naturally evolved TIPS mutants are highly (more than 180-fold) resistant t

65 scopy 26%; P = 0.418) and treatment failure (TIPS 38% vs. endoscopy 34%; P = 0.685) did not differ be

66 For TIPS-BP1' in room-temperature toluene, (1)TT formation i

67 For TIPS-BT1', the (1)TT is also observed to form rapidly (w

68 Among MESA participants eligible for TIPS, Poly-Iran, Wald, and the PILL Collaboration, CAC =

69 inine (P = 0.005), ascites as indication for TIPS (P = 0.04), and the presence of significant comorbi

70 often inpatients for whom an indication for TIPS had been refractory ascites, with a history of OHE

71 The most frequent indication for TIPS was refractory ascites (50 of 54; 93%).

72 Indications for TIPS were recurrent variceal bleeding (n = 25) and refra

73 1 (3.3%) patients with other indications for TIPS.

74 use of CFF could help selecting patients for TIPS.

75 , all patients with primary BCS referred for TIPS placement were included in the study.

76 andomized trial, we found covered stents for TIPS to increase the proportion of patients with cirrhos

77 r-like structures, novel configurations for +TIPS.

78 uent oxidation afford several functionalized TIPS-tetraazapentacene derivatives with energetically st

79 However, TIPS did not increase survival time or quality of life a

80 Here, we spatially image TIPS-pentacene microcrystals using ultrafast two-dimensi

81 The rapidity of (1)TT formation in TIPS-BT1' is at first glance surprising.

82 erage of crystalline and amorphous phases in TIPS-Pn films comprising a mixture of phases.

83 The E. indica TIPS EPSPS showed very high-level (2,647-fold) in vitro

84 obtained for a close constitutional isomer (TIPS-BT1) differing in the placement of TIPS-acetylene s

85 ars after traditional treatment, thus making TIPS appear to be not superior to endoscopy in survival

86 system based on the singlet fission material TIPS-Tc combined with PbS QDs.

87 the mechanism behind formation of metastable TIPS-pentacene polymorphs.

88 One-month TIPS venography demonstrated complete resolution of MPV

89 Mortality (TIPS 32% vs. endoscopy 26%; P = 0.418) and treatment fai

90 As the IPR never enters the MS, TIPS addresses two major drawbacks of IPC for ESI-MS: it

91 borylation/Chan-Lam procedure guided by an N-TIPS group enabled the conversion of a tryptophan deriva

92 iable routes were developed beginning with N-TIPS-pyrrole or with 4-oxo-2-pentene and TosMIC, affordi

93 ing singlet fission in these nanocrystalline TIPS-Pn films.

94 The first amino acid-Fmoc-O-TIPS-beta-tyrosine-was prepared in 78% yield (two steps

95 tion (median delay between administration of TIPS and first episode of dysfunction, 10.8 months).

96 uncovered stents counteracts the benefits of TIPS.

97 Finally, a comparison of TIPS-BT1' with previous results obtained for a close con

98 ma (LEE) is an underreported complication of TIPS creation.

99 hos (SL-J009-1) catalyze the C-C coupling of TIPS-protected propargyl ether 1a with primary alcohols

100 gh stereocontrol by [3 + 1]-cycloaddition of TIPS-protected enoldiazoacetates with alpha-acyl sulfur

101 The clinical effects of TIPS have been confirmed, however, no large-scale studie

102 controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in

103 ts (42%) experienced at least one episode of TIPS dysfunction (median delay between administration of

104 o oxygen and light, while analogous films of TIPS-pentacene showed full degradation after 4 days, sho

105 s for nanocrystalline and amorphous films of TIPS-Pn were estimated to be approximately 75 and approx

106 ading to one-dimensional (1D) growth mode of TIPS-pentacene crystals.

107 m led to two-dimensional (2D) growth mode of TIPS-pentacene crystals.

108 ents (9.2%) developed ELF within 3 months of TIPS (10 patients died, one required liver transplantati

109 Occlusion of TIPS was demonstrated in 84% of the patients, 63% of who

110 critical techniques and clinical outcome of TIPS on liver cirrhosis-related thrombotic total occlusi

111 t conditions: immediately after placement of TIPS (immediate PPG); at least 24 hours after placement

112 ortal hypertension who received placement of TIPS from January 2008 through October 2015; patients we

113 mer (TIPS-BT1) differing in the placement of TIPS-acetylene side groups suggests that the magnitude o

114 t types of PVT and technical success rate of TIPS is unclear.

115 The successful rate of TIPS was 90.7%, without any procedure-related deaths or

116 The overall success rate of TIPS was 95.8% (183/191).

117 sential for better technical success rate of TIPS.

118 ubstitution of the terminal aromatic ring of TIPS-tetracene by a thiadiazole group leads to a conside

119 The 2D spherulites of TIPS-pentacene are extremely advantageous for improving

120 ts for the observed much higher stability of TIPS-BT than TIPS-PT when mixed with PCBM.

121 a bending-induced ferroelastic transition of TIPS-P, flexible single-crystal electronic devices were

122 Most of the previous studies on TIPS procedure were based on the use of bare stents and

123 5 times the long-term survival than EEST or TIPS, and was much less costly than EEST or TIPS.

124 TIPS, and was much less costly than EEST or TIPS.

125 salvage for failure of endoscopic therapy or TIPS is not supported by the definitive results of these

126 p-TIPS in the setting of AVB is associated with a lower mo

127 lity rate in CP-B+AB patients was low, and p-TIPS did not improve it.

128 n preventing further bleeding and ascites, p-TIPS could be a good treatment strategy for CP-B+AB pati

129 Conclusion: p-TIPS must be the treatment of choice in CP-C patients wi

130 e of drugs and endoscopic therapy (D+E) or p-TIPS was based on individual center policy.

131 In CP-C and CP-B+AB patients, p-TIPS reduced treatment failure and rebleeding (1-year cu

132 sjugular intrahepatic portosystemic shunt (p-TIPS) has been shown to improve survival in these patien

133 double amino acid substitution (T102I+P106S [TIPS]) in the 5-enolpyruvylshikimate-3-phosphate synthas

134 tituted tetracene (TIPS-BT1') and pentacene (TIPS-BP1') dimers utilizing a [2.2.1] bicyclic norbornyl

135 bis(2-(tri-isopropylsilyl)ethynyl)pentacene (TIPS-pentacene).

136 ,13-bis(triisopropylsilylethynyl) pentacene (TIPS pentacene) was used as a model semiconductor materi

137 ,13-bis(triisopropylsilylethynyl) pentacene (TIPS-Pn), without the need for chemical modifications.

138 that bis(triisopropylsilylethynyl)pentacene (TIPS-P) crystals can undergo mechanically induced struct

139 6,13(bis-triisopropylsilylethynyl)pentacene (TIPS-pentacene), a small-molecule organic semiconductor,

140 6,13-bis(triisopropylsilylethynyl)pentacene (TIPS-pentacene), including a new polymorph discovered vi

141 6,13-bis(triisopropylsilylethynyl)pentacene (TIPS-pentacene).

142 6,13-bis(triisopropylsilylethynyl)pentacene, TIPS-pentacene) is blended with an insulating polymer (P

143 Post-TIPS OHE was more accurately predicted by CFF than by PH

144 Post-TIPS overt hepatic encephalopathy was present in 14 pati

145 as improving the long-term survival for post-TIPS patients.

146 ad a 100% negative predictive value for post-TIPS recurrent OHE.

147 Aiming to decrease the rate of post-TIPS HE, the use of CFF could help selecting patients fo

148 epatic encephalopathy was predictive of post-TIPS OHE and to compare Psychometric Hepatic Encephalopa

149 predictive value (91%) for the risk of post-TIPS recurrent OHE, defined as the occurrence of three o

150 The high rate of MPV patency post-TIPS placement suggests flow reestablishment as the domi

151 difference between the first and second post-TIPS placement acquisitions (all P > .11).

152 0.8 +/- 0.2 and 0.9 +/- 0.2 at the two post-TIPS time points, respectively, while the observed ratio

153 ient with refractory ascites at the two post-TIPS time points, respectively.

154 (462 vs. 443 ms; P = 0.05), an elevated pre-TIPS brain natriuretic peptide (BNP) or N-terminal pro-b

155 The absence of pre-TIPS history of OHE and a CFF value equal to or greater

156 Results Pre-TIPS demographics and clinical characteristics of the tw

157 ospective study was to determine whether pre-TIPS minimal hepatic encephalopathy was predictive of po

158 d to further validate the role of preemptive TIPS in a large number of high-risk patients.

159 As compared to pristine TIPS pentacene devices, bottom-gate, top-contact OTFTs w

160 By tracking MT +end-binding proteins (+TIPS) in Aspergillus nidulans, we find that MTs are regu

161 At PVR-TIPS completion, persistence of MPV thrombus was noted i

162 We evaluated the impact of PVR-TIPS on liver function, transplant eligibility, and long

163 The PVR-TIPS may be considered for patients with obliterative PV

164 gery/radiology, these patients underwent PVR-TIPS to potentiate transplant eligibility.

165 lored with the ethynylbenziodoxolone reagent TIPS-EBX employing an Ir(III) catalyst.

166 e hypervalent iodine alkyne transfer reagent TIPS-ethynyl-benziodoxolone has been developed.

167 reas 88.89% of 9 patients who didn't receive TIPS procedure (2 in acute group).

168 underwent EEST and 61% of those who received TIPS.

169 Furthermore, the decisions regarding TIPS and additional endovascular procedures in patients

170 102I mutation to create the highly resistant TIPS EPSPS.

171 we call this transient ion-pair separation (TIPS).

172 Multivariable analysis showed TIPS creation for ascites (odds ratio, 1.7; 95% CI: 1.04

173 Required several revisions of the shunt TIPS can be performed in case of different conditions su

174 ansjugular intrahepatic portosystemic shunt (TIPS) as a treatment for BCS with diffuse occlusion of h

175 ansjugular intrahepatic portosystemic shunt (TIPS) as second-line therapeutic options.

176 ansjugular intrahepatic portosystemic shunt (TIPS) correlates with the absence of further bleeding or

177 ansjugular intrahepatic portosystemic shunt (TIPS) creation in patients with cirrhosis with Model for

178 ansjugular intrahepatic portosystemic shunt (TIPS) creation is an accepted treatment of portal hypert

179 ansjugular intrahepatic portosystemic shunt (TIPS) creation performed by using a 10-mm or an 8-mm-dia

180 ansjugular intrahepatic portosystemic shunt (TIPS) creation, regardless of left ventricular function.

181 ansjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hypertension.

182 ansjugular intrahepatic portosystemic shunt (TIPS) has been worldwide considered as a noninvasive tec

183 ansjugular intrahepatic portosystemic shunt (TIPS) in a series of patients with Budd-Chiari syndrome

184 ansjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hypertension may be consid

185 ansjugular intrahepatic portosystemic shunt (TIPS) in this population are unknown.

186 ansjugular intrahepatic portosystemic shunt (TIPS) is now a standard for the treatment of portal hype

187 ansjugular intrahepatic portosystemic shunt (TIPS) placement in patients who are deemed 'difficult' t

188 ansjugular intrahepatic portosystemic shunt (TIPS) placement.

189 ansjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT.

190 ansjugular intrahepatic portosystemic shunt (TIPS) was created to facilitate the outflow from the tre

191 ansjugular intrahepatic portosystemic shunt (TIPS) with covered stents in patients receiving standard

192 ansjugular intrahepatic portosystemic shunt (TIPS).

193 ansjugular intrahepatic portosystemic shunt (TIPS).

194 ansjugular intrahepatic portosystemic shunt (TIPS).

195 ular intrahepatic portosystemic stent shunt (TIPS).

196 ular intrahepatic portosystemic stent-shunt (TIPS) (8 mm; n = 90), or medical reduction of portal pre

197 sjugular intrahepatic portal-systemic shunt (TIPS) performed when bleeding is not controlled.

198 jugular intrahepatic portosystemic shunting (TIPS), and orthotopic liver transplantation (OLT).

199 nsjugular intrahepatic portosystemic shunts (TIPS) is a second-line treatment because of an increased

200 nsjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrho

201 nsjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrho

202 jugular intrahepatic Porto systemic shunts (TIPS) procedure (1).

203 Standard TIPS procedure was not feasible due to altered anatomy o

204 ion of one photoexcited and one ground-state TIPS-pentacene molecule.

205 ent of solution-sheared and lattice-strained TIPS-pentacene crystals.

206 lthough vertical phase-separated structures (TIPS-pentacene-top/PS-bottom) were formed on the substra

207 ed using the criteria of 4 polypill studies (TIPS [The Indian Polycap Study], Poly-Iran, Wald, and th

208 These findings support TIPS as the first-line intervention in such patients.

209 efined TIPS-acetylene substituted tetracene (TIPS-BT1') and pentacene (TIPS-BP1') dimers utilizing a

210 served much higher stability of TIPS-BT than TIPS-PT when mixed with PCBM.

211 There was suggestion that TIPS creation for ascites might be an underlying risk fa

212 The TIPS venography and serial ultrasound/MRI were used subs

213 After the TIPS procedure, 19 patients (35%) experienced a total of

214 After the TIPS procedure, incidence and risk factors of cardiac de

215 splenic vein (SV), portal vein (PV), and the TIPS.

216 any days of hospitalization (35 days) as the TIPS group (17 days) (P = .04).

217 In those with resolved ascites, the TIPS-to-PV flow ratio was 0.8 +/- 0.2 and 0.9 +/- 0.2 at

218 year) was significantly more frequent in the TIPS group (35% vs. 14%; P = 0.035), but during long-ter

219 A higher proportion of patients in the TIPS group (93%) met the primary end point than in the L

220 lightly higher proportion of patients in the TIPS group experienced adverse events, including encepha

221 cantly smaller proportion of patients in the TIPS group had rebleeding within 2 years (7%) than in th

222 e total number of paracenteses was 32 in the TIPS group vs 320 in the LVP+A group.

223 as compared to 0 of 37 (0%) patients in the TIPS group, developed variceal rebleeding (P = 0.001).

224 mplications (18% vs 0%; P = .01) than in the TIPS group.

225 raction (<10%) of the amorphous phase in the TIPS-Pn films greatly decreased the ultimate triplet dif

226 rtal-venous shunting, with draining into the TIPS.

227 Removal of the TIPS group to form the isolable beta-keto ester precedes

228 The sequential evolution of the TIPS mutation endowing high-level glyphosate resistance

229 The evolution of the TIPS mutation in crop fields under glyphosate selection

230 measured immediately after placement of the TIPS, when different circumstances can affect PPG values

231 he spin time governed the growth mode of the TIPS-pentacene molecules that phase-separated and crysta

232 rom the early PPG, regardless of whether the TIPS was placed using general anesthesia (8.5 +/- 3.5 mm

233 These TIPS-TAPs are either crystalline or amorphous, depending

234 This TIPS mutation recreates the biotechnology-engineered com

235 Thus, in contrast to TIPS-tetracene, SF becomes exothermic for various PTD de

236 e PPG); at least 24 hours after placement to TIPS into hemodynamically stable patients, without sedat

237 h cirrhosis and acute BEV were randomized to TIPS (n=78) or EPCS (n=76).

238 rotonation of [U(Tren(TIPS))(NH2)] (1) [Tren(TIPS) = N(CH2CH2NSiPr(i)3)3] with organoalkali metal rea

239 Reaction of [U(Tren(TIPS) )(PH2 )] (1, Tren(TIPS) =N(CH2 CH2 NSiPr(i)3 )3 ) with C6 H5 CH2 K and [U(

240 Reaction of [U(Tren(TIPS))] [1, Tren(TIPS)=N(CH2CH2NSiiPr3)3] with 0.25 equivalents of P4 rep

241 ion of [U(Tren(TIPS) )(THF)][BPh4 ] (1; Tren(TIPS) =N{CH2 CH2 NSi(iPr)3 }3 ) with NaPH2 afforded the

242 reduction of [Th(Tren(TIPS) )(OCP)] (2, Tren(TIPS) =[N(CH(2) CH(2) NSiPr(i) (3) )](3-) ), with RbC(8)

243 nium(VI) nitride [U(Tren(TIPS))(N)] (2, Tren(TIPS)=N(CH2CH2NSiiPr3)3) with CO gave the uranium(IV) cy

244 on to give [U(Tren(TIPS) )(CHEPh(3) )] (Tren(TIPS) =N(CH(2) CH(2) NSiPr(i) (3) )(3) ; E=As, 2As; P, 2

245 ) )}2 (mu-eta(2) :eta(2) -As2 H2 )] (3, Tren(TIPS) =N(CH2 CH2 NSiPr(i) 3 )3 ; Pr(i) =CH(CH3 )2 ).

246 [An(Tren(DMBS) ){Pn(SiMe3 )2 }] and [An(Tren(TIPS) ){Pn(SiMe3 )2 }] [Tren(DMBS) =N(CH2 CH2 NSiMe2 Bu(

247 n=U, Pn=P, As, Sb, Bi; An=Th, Pn=P, As; Tren(TIPS) =N(CH2 CH2 NSiPr(i)3 )3 , An=U, Pn=P, As, Sb; An=T

248 hat reduction of [U(Tren(TIPS) )(OCP)] (Tren(TIPS) =N(CH(2) CH(2) NSiPr(i) (3) )(3) ) with KC(8) /2,2

249 (O)mu-P]}] (3) and the oxo complex [{Th(Tren(TIPS) )(mu-OCs)}(2) ] (7) were isolated.

250 be converted to a rare oxo complex [{Th(Tren(TIPS) )(mu-ORb)}(2) ] (6) and the known cyclometallated

251 We report that reduction of [Th(Tren(TIPS) )(OCP)] (2, Tren(TIPS) =[N(CH(2) CH(2) NSiPr(i) (3

252 n products that then decompose with [Th(Tren(TIPS) )O](-) essentially acting as a protecting then lea

253 unprecedented hexathorium complex [{Th(Tren(TIPS) )}(6) (mu-OC(2) P(3) )(2) (mu-OC(2) P(3) H)(2) Rb(

254 idiide C-H bond activation product [{Th(Tren(TIPS) )}Th{N(CH(2) CH(2) NSiPr(i) (3) )(2) [CH(2) CH(2)

255 by alpha-proton abstraction to give [U(Tren(TIPS) )(CHEPh(3) )] (Tren(TIPS) =N(CH(2) CH(2) NSiPr(i)

256 Here, we report that reduction of [U(Tren(TIPS) )(OCP)] (Tren(TIPS) =N(CH(2) CH(2) NSiPr(i) (3) )(

257 erminal parent phosphinidene complex [U(Tren(TIPS) )(PH)][K(B15C5)2 ] (4; UP=2.613(2) A).

258 Alternatively, reaction of [U(Tren(TIPS) )(PH)][Na(12C4)2 ] (5, 12C4=12-crown-4 ether) with

259 Reaction of [U(Tren(TIPS) )(PH2 )] (1, Tren(TIPS) =N(CH2 CH2 NSiPr(i)3 )3 )

260 ck terminal parent phosphide complex [U(Tren(TIPS) )(PH2 )] (2; U-P=2.883(2) A).

261 Reaction of [U(Tren(TIPS) )(THF)][BPh4 ] (1; Tren(TIPS) =N{CH2 CH2 NSi(iPr)3

262 NSiPr(i)3 )3 ) with C6 H5 CH2 K and [U(Tren(TIPS) )(THF)][BPh4 ] (2) afforded a rare diuranium paren

263 ) with KC(8) /2,2,2-cryptand gives [{U(Tren(TIPS) )}(2) {mu-eta(2) (OP):eta(2) (CP)-OCP}][K(2,2,2-cr

264 the diuranium mu-phosphido complex [{U(Tren(TIPS) )}(mu-P){U(Tren(DMBS) )}][Na(12C4)2 ] [7, Tren(DMB

265 HAsAsH in the diuranium(IV) complex [{U(Tren(TIPS) )}2 (mu-eta(2) :eta(2) -As2 H2 )] (3, Tren(TIPS) =

266 the diuranium mu-phosphido complex [{U(Tren(TIPS) )}2 (mu-P)][K(B15C5)2 ] (4).

267 anium parent phosphinidiide complex [{U(Tren(TIPS) )}2 (mu-PH)] (3).

268 ) afforded the imido-bridged dimers [{U(Tren(TIPS))(mu-N[H]M)}2] [M = Li-Cs (2a-e)].

269 onylation of the uranium(VI) nitride [U(Tren(TIPS))(N)] (2, Tren(TIPS)=N(CH2CH2NSiiPr3)3) with CO gav

270 ve 1 and the uranium-nitride complex [U(Tren(TIPS))(N)] (5); this reaction is a new way to prepare th

271 can be prepared directly from CO and [U(Tren(TIPS))(N)][K(B15C5)2] (7).

272 from CO and the uranium(V) nitride [{U(Tren(TIPS))(N)K}2] (6), with or without B15C5, respectively.

273 with CO gave the uranium(IV) cyanate [U(Tren(TIPS))(NCO)] (3).

274 4) and KNCO, or cyanate retention in [U(Tren(TIPS))(NCO)][K(B15C5)2] (5, B15C5=benzo-15-crown-5 ether

275 ranium terminal parent imido complex [U(Tren(TIPS))(NH)] (4) resulted in spontaneous disproportionati

276 ranium terminal parent imido complex [U(Tren(TIPS))(NH)][K(15C5)2] (3c), which can also be viewed as

277 Deprotonation of [U(Tren(TIPS))(NH2)] (1) [Tren(TIPS) = N(CH2CH2NSiPr(i)3)3] with

278 lted in cyanate dissociation to give [U(Tren(TIPS))] (4) and KNCO, or cyanate retention in [U(Tren(TI

279 Reaction of [U(Tren(TIPS))] [1, Tren(TIPS)=N(CH2CH2NSiiPr3)3] with 0.25 equi

280 inverted sandwich cyclo-P5 complex [{U(Tren(TIPS))}2(mu-eta(5):eta(5)-cyclo-P5)] (2).

281 to a catalytic amount of iron(II) triflate, TIPS-protected peroxides bearing primary, secondary, and

282 ethylformamide, Tf=trifluoromethanesulfonyl, TIPS=triisopropylsilyl.

283 n solutions of bis(triisopropylsilylethynyl (TIPS)) pentacene.

284 d solutions of bis(triisopropylsilylethynyl)[TIPS]--tetracene we find rapid (<100 ps) formation of ex

285 with a MELD score of 12 or less who undergo TIPS placement for refractory ascites (especially in pat

286 noncirrhotic portal hypertension undergoing TIPS in seven centers between 2000 and 2014 were retrosp

287 All patients >/= 18 years old undergoing TIPS during a hospital admission (n = 5529) without conc

288 [CI]: 57.2 years, 60.3 years) had undergone TIPS placement by using 10-mm (60 patients) or 8-mm (111

289 ients from the medical group (16%) underwent TIPS placement during follow-up evaluation, mainly for r

290 he medical records of patients who underwent TIPS creation between January 2003 and April 2019 at Ore

291 cience University and patients who underwent TIPS creation between January 2006 and December 2016 at

292 eline MELD score of 12 or less who underwent TIPS placement between September 1999 and July 2012 were

293 mortality rate of 91 patients who underwent TIPS was 6.59% (6/91), whereas 88.89% of 9 patients who

294 n 84% of the patients, 63% of whom underwent TIPS revision, which failed in 80% of the cases.

295 y to numerous endoscopic treatments in which TIPS was considered in an attempt to decrease the risk o

296 n + beta-blocker treatment was compared with TIPS placement in 72 patients with a first or second epi

297 All patients with cirrhosis treated with TIPS between May 2011 and June 2016 were considered for

298 otic total occlusion of MPV and treated with TIPS from January 2000 to January 2010 were retrospectiv

299 y 2011, 54 consecutive patients treated with TIPS were included.

300 this study and 91 patients were treated with TIPS.